Clinical trials
Rhabdomyosarcoma clinical trials
Below are recruiting rhabdomyosarcoma clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05033288Recruiting
Compare radiation types and surgery for pelvic bone sarcomas
This study compares three treatment approaches—carbon ion radiation, proton radiation, and surgery—for sarcomas in the pelvis that involve bone. It looks to see which option best controls the tumor while helping protect nearby tissues.
Scottsdale, ArizonaAges 15 years+ - NCT05108298Recruiting
Study to improve cancer survey reporting for young adults
This study focuses on collecting better self-reported information (from questionnaires) from young adults with cancer. It may help improve how future cancer trials understand symptoms and quality-of-life needs.
Fairbanks, AlaskaAges 18–39 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT06094101RecruitingPhase 1/Phase 2
Personalized vaccine for fusion-positive sarcoma patients
This trial tests a personalized vaccine made from your tumor's unique gene fusion. It's for people with certain sarcomas that have spread and are now in remission or stable after standard treatment. The vaccine aims to help your immune system keep the cancer from coming back.
EssenAges 2–40 - NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT06277154RecruitingPhase 2
MASCT-I plus chemo for first-line advanced soft tissue sarcoma
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
GuangzhouAges 18–70 - NCT06456892RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for children with hard-to-treat rhabdomyosarcoma
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
Guangzhou, GuangdongAges 1–18 - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06684327RecruitingPhase 2
Study of three chemotherapy drugs for rare advanced cancers
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT07054944Recruiting
Lymph node mapping for children with solid tumors
This study is testing a new way to map lymph nodes in children with solid tumors. It helps doctors understand how tumors spread to lymph nodes, which may guide treatment.
Rochester, New YorkAges 1 month–17 years - NCT07148050RecruitingPhase 1
CAR T-cell therapy for children with solid tumors
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Seattle, WashingtonAges 1–26 - NCT07169344RecruitingPhase 2
Short course radiation before sarcoma surgery
This trial tests a shorter, 3-week course of radiation therapy (using protons or standard X-rays) given before surgery for localized soft tissue sarcoma. It aims to see if this approach is safe and effective for treating the tumor while reducing side effects.
BergenAges 18 years+ - NCT07173972RecruitingPhase 2
Proton radiation for inoperable soft tissue sarcoma
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
BergenAges 18 years+ - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Birmingham, AlabamaAges Up to 30 years - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years - NCT06625190RecruitingPhase 1/Phase 2
Half-matched transplant with zoledronic acid for resistant solid tumors
This trial tests a new approach using a special type of transplant (with cells from a half-matched family donor) plus a drug called zoledronic acid. It is for children and young adults with certain solid tumors that have not responded to standard treatments.
Gainesville, FloridaAges 6 months–25 years - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT07628634RecruitingEarly Phase 1
Testing a Low-Methionine Diet in Solid Tumor Patients
This early-stage study explores whether eating a diet low in methionine (a natural amino acid found in protein) might help people with advanced solid tumors. Researchers will track how this dietary change affects blood levels and may improve treatment outcomes alongside standard cancer care.
Orange, CaliforniaAges 18 years+ - NCT03054792Enrolling by invitationPhase 1
MRI test to map low-oxygen areas in childhood sarcomas
This Phase 1 study uses special MRI scans to look at “low-oxygen” parts of a childhood sarcoma. It aims to help doctors better understand the tumor before standard treatment that may include chemotherapy and sometimes radiation.
Toronto, OntarioAges 6–18
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rhabdomyosarcoma?
- Yes. Clin2 currently lists 45 recruiting rhabdomyosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rhabdomyosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rhabdomyosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.